Sarepta Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $123.68
- Today's High:
- $126.4
- Open Price:
- $125.88
- 52W Low:
- $61.28
- 52W High:
- $159.89
- Prev. Close:
- $124.28
- Volume:
- 869200
Company Statistics
- Market Cap.:
- $11.66 billion
- Book Value:
- 7.652
- Revenue TTM:
- $975.68 million
- Operating Margin TTM:
- -59.59%
- Gross Profit TTM:
- $-78066000
- Profit Margin:
- -114.3%
- Return on Assets TTM:
- -11.88%
- Return on Equity TTM:
- -142.1%
Company Profile
Sarepta Therapeutics Inc had its IPO on 1997-06-03 under the ticker symbol SRPT.
The company operates in the Healthcare sector and Biotechnology industry. Sarepta Therapeutics Inc has a staff strength of 1,162 employees.
Stock update
Shares of Sarepta Therapeutics Inc opened at $125.88 at the start of the last trading session i.e. 2023-06-03.
The stocks traded within a range of $123.68 - $126.4, and closed at $125.16.
This is a +0.71% increase from the previous day's closing price.
A total volume of 869,200 shares were traded at the close of the day’s session.
In the last one week, shares of Sarepta Therapeutics Inc have slipped by -4.72%.
Sarepta Therapeutics Inc's Key Ratios
Sarepta Therapeutics Inc has a market cap of $11.66 billion, indicating a price to book ratio of 25.7374 and a price to sales ratio of 12.4903.
In the last 12-months Sarepta Therapeutics Inc’s revenue was $975.68 million with a gross profit of $-78066000 and an EBITDA of $-539008000. The EBITDA ratio measures Sarepta Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Sarepta Therapeutics Inc’s operating margin was -59.59% while its return on assets stood at -11.88% with a return of equity of -142.1%.
In Q1, Sarepta Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 20.2%.
Sarepta Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 159.25
Its diluted EPS in the last 12-months stands at $-12.76 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 159.25. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sarepta Therapeutics Inc’s profitability.
Sarepta Therapeutics Inc stock is trading at a EV to sales ratio of 12.0932 and a EV to EBITDA ratio of -17.4683. Its price to sales ratio in the trailing 12-months stood at 12.4903.
Sarepta Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $3.06 billion
- Total Liabilities
- $536.88 million
- Operating Cash Flow
- $12.49 million
- Capital Expenditure
- $9.49 million
- Dividend Payout Ratio
- 0%
Sarepta Therapeutics Inc ended 2023 with $3.06 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $3.06 billion while shareholder equity stood at $712.75 million.
Sarepta Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $536.88 million in other current liabilities, 9000.00 in common stock, $-4426991000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $871.67 million and cash and short-term investments were $1.88 billion. The company’s total short-term debt was $0 while long-term debt stood at $1.23 billion.
Sarepta Therapeutics Inc’s total current assets stands at $2.49 billion while long-term investments were $31.00 million and short-term investments were $1.01 billion. Its net receivables were $288.08 million compared to accounts payable of $106.71 million and inventory worth $202.68 million.
In 2023, Sarepta Therapeutics Inc's operating cash flow was $12.49 million while its capital expenditure stood at $9.49 million.
Comparatively, Sarepta Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $125.16
- 52-Week High
- $159.89
- 52-Week Low
- $61.28
- Analyst Target Price
- $175.68
Sarepta Therapeutics Inc stock is currently trading at $125.16 per share. It touched a 52-week high of $159.89 and a 52-week low of $159.89. Analysts tracking the stock have a 12-month average target price of $175.68.
Its 50-day moving average was $131.64 and 200-day moving average was $122.68 The short ratio stood at 2.23 indicating a short percent outstanding of 0%.
Around 425.3% of the company’s stock are held by insiders while 8535.2% are held by institutions.
Frequently Asked Questions About Sarepta Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children’s Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.